Compare Ascendis Pharma A/S (ASND) vs United States Oil ETF (USO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs United States Oil ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while United States Oil ETF trades at $111.42. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, United States Oil ETF nearer its low. Which is the better fit depends on your goals.
| ASND | USO | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | — |
52-Week High | $277.18 | $152.96 |
52-Week Low | $163.32 | $66.17 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
USO trades at $108.7, down 0.29% today, with a neutral technical signal and bearish moving averages. Recent news highlights oil price volatility driven by geopolitical tensions, including a 7% spike in WTI crude and Russia's diesel export ban. Support and resistance levels are tightly clustered, indicating potential for near-term price movement.
The outlook for USO is influenced by oil market dynamics, with supply risks from Middle East conflicts and strategic reserve buying providing support. However, risks include potential demand declines and geopolitical resolutions that could pressure prices. Investors should weigh these factors against current technical neutrality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →
